Moran Wealth Management LLC Has $3.71 Million Stock Position in Smith & Nephew SNATS, Inc. $SNN

Moran Wealth Management LLC increased its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 3.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 121,052 shares of the medical equipment provider’s stock after purchasing an additional 3,667 shares during the period. Moran Wealth Management LLC’s holdings in Smith & Nephew SNATS were worth $3,708,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hexagon Capital Partners LLC grew its stake in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. lifted its holdings in shares of Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 1,000 shares during the period. Bessemer Group Inc. boosted its position in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,701 shares in the last quarter. Banque Transatlantique SA bought a new position in Smith & Nephew SNATS in the first quarter valued at approximately $52,000. Finally, GAMMA Investing LLC raised its position in Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider’s stock valued at $103,000 after purchasing an additional 666 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Up 0.3%

Shares of SNN stock opened at $35.35 on Thursday. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $38.79. The stock’s fifty day simple moving average is $36.71 and its 200 day simple moving average is $31.59. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $15.09 billion, a P/E ratio of 16.37, a P/E/G ratio of 0.97 and a beta of 0.69.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a $0.285 dividend. This represents a yield of 165.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio (DPR) is 26.39%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SNN shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, October 8th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 3rd. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the company a “market perform” rating in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, August 18th. Eight research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $36.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.